High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial

Jan Dörr, Priscilla Bäcker-Koduah, Klaus-Dieter Wernecke, Elke Becker, Frank Hoffmann, Jürgen Faiss, Bernd Brockmeier, Olaf Hoffmann, Kerstin Anvari, Jens Wuerfel, Sophie K Piper, Judith Bellmann-Strobl, Alexander U Brandt, Friedemann Paul, Jan Dörr, Priscilla Bäcker-Koduah, Klaus-Dieter Wernecke, Elke Becker, Frank Hoffmann, Jürgen Faiss, Bernd Brockmeier, Olaf Hoffmann, Kerstin Anvari, Jens Wuerfel, Sophie K Piper, Judith Bellmann-Strobl, Alexander U Brandt, Friedemann Paul

Abstract

Background: Epidemiological, preclinical, and non-interventional studies link vitamin D (VD) serum levels and disease activity in multiple sclerosis (MS). It is unclear whether high-dose VD supplementation can be used as an intervention to reduce disease activity.

Objectives: The study aimed to compare the effects of every other day high- (20,400 IU) versus low-dose (400 IU) cholecalciferol supplementation on clinical and imaging markers of disease activity in patients with relapsing-remitting MS or clinically isolated syndrome.

Methods: The EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial was a multicentre randomized/stratified actively controlled explorative phase 2a pilot trial with a double-blind intervention period of 18 months, add on to interferon-β1b.

Results: Fifty-three patients were randomized, and 41 patients completed the study. Cholecalciferol supplementation was well tolerated and safe in both arms. After 18 months, clinical (relapse rates, disability progression) and radiographical (T2-weighted lesion development, contrast-enhancing lesion development, brain atrophy) did not differ between both treatment arms. Post-study power calculations suggested that the sample size was too low to prove the hypothesis.

Conclusions: The results neither support nor disprove a therapeutic benefit of high-dose VD supplementation but provide a basis for sound sample size estimations in future confirmatory studies. www.clinicaltrials.gov/NCT01440062.

Keywords: Multiple sclerosis; clinical trial; efficacy; supplementation; treatment; vitamin D.

© The Author(s) 2020.

Figures

Figure 1.
Figure 1.
The CONSORT flow diagram. Figure 1 shows the numbers of screened, randomized, and analysed patients in both treatment arms. The reasons for exclusion from randomization, drop out or exclusion from analysis are displayed. ITT: intention to treat; PP: per protocol; n: number.

References

    1. Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther 2018; 7: 59–85.
    1. Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J 2013; 4: 4.
    1. Koduah P, Paul F, Dörr J-M. Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J 2017; 8: 313–325.
    1. Kimball SM, Ursell MR, O’Connor Pet al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645–651.
    1. McLaughlin L, Clarke L, Khalilidehkordi Eet al. Vitamin D for the treatment of multiple sclerosis: A meta-analysis. J Neurol 2018; 265: 2893–2905.
    1. Shoemaker TJ, Mowry EM. A review of vitamin D supplementation as disease-modifying therapy. Mult Scler 2018; 24: 6–11.
    1. Burton JM, Kimball S, Vieth Ret al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852–1859.
    1. Soilu-Hänninen M, Aivo J, Lindström B-Met al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 565–571.
    1. Kampman MT, Steffensen LH, Mellgren SIet al. Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18: 1144–1151.
    1. Hupperts R, Smolders J, Vieth Ret al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology 2019; 93: e1906–e1916.
    1. Dörr J, Ohlraun S, Skarabis Het al. Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial. Trials 2012; 13: 15.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.
    1. Cutter GR, Baier ML, Rudick RAet al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain J Neurol 1999; 122: 871–882.
    1. Polman CH, Reingold SC, Edan Get al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58: 840–846.
    1. Smith SM, Zhang Y, Jenkinson Met al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.
    1. Smith SM, Jenkinson M, Woolrich MWet al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23: S208–S219.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren